# OnCo record paper-drilon-larotrectinib-nejm-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-drilon-larotrectinib-nejm-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-drilon-larotrectinib-nejm-2018" ;
  schema:name "Larotrectinib in TRK fusion-positive cancers in adults and children"@en ;
  schema:description "The selective TRK inhibitor larotrectinib shrank tumours in three quarters of patients with NTRK fusions across 17 different cancer types and ages from infancy to old age, leading to the first tumour-agnostic approval of a targeted drug."@en ;
  schema:url <https://onco.cc/key-papers/paper-drilon-larotrectinib-nejm-2018/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1714448>, <https://pubmed.ncbi.nlm.nih.gov/29466156/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1714448> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Drilon A, Laetsch TW, Kummar S, et al." ;
  onco:cancers <https://onco.cc/cancers/ntrk-fusion-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/larotrectinib/> ;
  onco:journals <https://onco.cc/journals/nejm/> .